These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 32065862)
1. Assessment of high-grade prostate cancer risk using prostate cancer biomarkers. Stanton WN; Crawford ED; Arangua PB; La Rosa FG; van Bokhoven A; Lucia MS; Poage WL; Partin A; Maroni P; Werahera PN Can J Urol; 2020 Feb; 27(1):10080-10085. PubMed ID: 32065862 [TBL] [Abstract][Full Text] [Related]
2. Concordance and Performance of 4Kscore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer. Wysock JS; Becher E; Persily J; Loeb S; Lepor H Urology; 2020 Jul; 141():119-124. PubMed ID: 32294481 [TBL] [Abstract][Full Text] [Related]
3. Prospective validation of microseminoprotein-β added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort. Lonergan PE; Vertosick EA; Assel M; Sjoberg DD; Haese A; Graefen M; Boorjian SA; Klee GG; Cooperberg MR; Pettersson K; Routila E; Vickers AJ; Lilja H BJU Int; 2021 Aug; 128(2):218-224. PubMed ID: 33306251 [TBL] [Abstract][Full Text] [Related]
4. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore. Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698 [TBL] [Abstract][Full Text] [Related]
5. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884 [TBL] [Abstract][Full Text] [Related]
6. A 4Kscore Cut-off of 7.5% for Prostate Biopsy Decisions Provides High Sensitivity and Negative Predictive Value for Significant Prostate Cancer. Bhattu AS; Zappala SM; Parekh DJ; Punnen S Urology; 2021 Feb; 148():53-58. PubMed ID: 33217456 [TBL] [Abstract][Full Text] [Related]
7. Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial. Josefsson A; Månsson M; Kohestani K; Spyratou V; Wallström J; Hellström M; Lilja H; Vickers A; Carlsson SV; Godtman R; Hugosson J Eur Urol; 2024 Sep; 86(3):223-229. PubMed ID: 38772787 [TBL] [Abstract][Full Text] [Related]
8. Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10-20 ng/mL and normal digital rectal examination. Chiu PK; Teoh JY; Lee WM; Yee CH; Chan ES; Hou SM; Ng CF Investig Clin Urol; 2016 Sep; 57(5):336-42. PubMed ID: 27617315 [TBL] [Abstract][Full Text] [Related]
9. Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy. Nordström T; Adolfsson J; Grönberg H; Eklund M BMC Urol; 2017 Oct; 17(1):92. PubMed ID: 28974201 [TBL] [Abstract][Full Text] [Related]
10. The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort. Möller A; Olsson H; Grönberg H; Eklund M; Aly M; Nordström T Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):137-142. PubMed ID: 30171228 [TBL] [Abstract][Full Text] [Related]
11. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years. Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705 [TBL] [Abstract][Full Text] [Related]
12. The 4Kscore Predicts the Grade and Stage of Prostate Cancer in the Radical Prostatectomy Specimen: Results from a Multi-institutional Prospective Trial. Punnen S; Nahar B; Prakash NS; Sjoberg DD; Zappala SM; Parekh DJ Eur Urol Focus; 2017 Feb; 3(1):94-99. PubMed ID: 28720374 [TBL] [Abstract][Full Text] [Related]
13. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. McKiernan J; Donovan MJ; O'Neill V; Bentink S; Noerholm M; Belzer S; Skog J; Kattan MW; Partin A; Andriole G; Brown G; Wei JT; Thompson IM; Carroll P JAMA Oncol; 2016 Jul; 2(7):882-9. PubMed ID: 27032035 [TBL] [Abstract][Full Text] [Related]
14. Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study. Jamnagerwalla J; Howard LE; Allott EH; Vidal AC; Moreira DM; Castro-Santamaria R; Andriole GL; Freeman MR; Freedland SJ Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):252-259. PubMed ID: 29282360 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic Impacts of Clinical Laboratory Based p2PSA Indexes on any Grade, Gleason Grade Group 2 or Greater, or 3 or Greater Prostate Cancer and Prostate Specific Antigen below 10 ng/ml. Ito K; Yokomizo A; Tokunaga S; Arai G; Sugimoto M; Akakura K; Hasumi H; Sakai H; Ouraji A; Oki R; Kashiwagi E; Kobori Y; Hirama H; Kitoh H; Uemura H; Hakariya T; Suzuki K; J Urol; 2020 Jan; 203(1):83-91. PubMed ID: 31430244 [TBL] [Abstract][Full Text] [Related]
16. A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men. Punnen S; Freedland SJ; Polascik TJ; Loeb S; Risk MC; Savage S; Mathur SC; Uchio E; Dong Y; Silberstein JL J Urol; 2018 Jun; 199(6):1459-1463. PubMed ID: 29223389 [TBL] [Abstract][Full Text] [Related]
17. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination. Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560 [TBL] [Abstract][Full Text] [Related]
18. The application of p2PSA% and prostate health index in prostate cancer detection: A prospective cohort in a Tertiary Medical Center. Cheng YT; Chiang CH; Pu YS; Liu SP; Lu YC; Chang YK; Chang HC; Huang KH; Lee YJ; Chow PM; Hung SC; Huang CY J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):260-267. PubMed ID: 29779925 [TBL] [Abstract][Full Text] [Related]
19. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. Thompson IM; Ankerst DP; Chi C; Lucia MS; Goodman PJ; Crowley JJ; Parnes HL; Coltman CA JAMA; 2005 Jul; 294(1):66-70. PubMed ID: 15998892 [TBL] [Abstract][Full Text] [Related]
20. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. Thompson IM; Pauler DK; Goodman PJ; Tangen CM; Lucia MS; Parnes HL; Minasian LM; Ford LG; Lippman SM; Crawford ED; Crowley JJ; Coltman CA N Engl J Med; 2004 May; 350(22):2239-46. PubMed ID: 15163773 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]